ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

2 Day Online Training Course - Implementing CSA for GxP Systems - Transition, Documentation, and Post-Transition Challenges and Opportunities (Oct 16th - Oct 17th, 2025) - ResearchAndMarkets.com

The "Implementing CSA for GxP Systems - Transition, Documentation, and Post-Transition Challenges and Opportunities (Oct 16th - Oct 17th, 2025)" training has been added to ResearchAndMarkets.com's offering.

This 2-day online course provides an in-depth guide to implementing Computer Software Assurance (CSA) for GxP-regulated systems.

Computer system validation has been regulated by FDA for more than 30 years, as it relates to systems used in the manufacturing, testing and distribution of a product in the pharmaceutical, biotechnology, medical device or other FDA-regulated industries. The FDA requirements ensure thorough planning, implementation, integration, testing and management of computer systems used to collect, analyze and/or report data.

Electronic records and electronic signatures (ER/ES) came into play through guidelines established by FDA in 1997, and disseminated through 21 CFR Part 11. This code describes the basic requirements for validating and documenting ER/ES capability in systems used in an FDA-regulated environment.

In the early 2000s, FDA recognized they could not inspect every computer system at every regulated company and placed the onus on industry to begin assessing all regulated computer systems based on risk. The level of potential risk, should the system fail to operate properly, needed to be the basis for each company's approach to developing a validation approach and rationale as part of the planning process. System size, complexity, business criticality, GAMP5 category and risk rating are the five key components for determining the scope and robustness of testing required to ensure data integrity and product safety.

Until recently, the traditional approach to Computer System Validation (CSV) was believed to be required by FDA. It was also believed that following GAMP5 practices was also a requirement. While FDA will tell industry WHAT is required, they have never dictated HOW those requirements should be met. Each company that is FDA-regulated must use critical thinking, as described in the CSA approach to come up with the most practical and innovative way to adhere to the regulations. They still must meet WHAT FDA requires, but HOW must be evaluated and determined in order to comply.

GAMP5, Second Edition aligns well with CSA, and the two used in concert can provide a more effective and efficient means of reaching compliance for computer systems used in regulated processes.

Why Should You Attend

This Seminar is intended for those involved in planning, execution and support of computer system validation activities, working in the FDA-regulated industries, including pharmaceutical, medical device, biologics, tobacco and tobacco-related products (e-liquids, e-cigarettes, pouch tobacco, cigars, etc.).

Attendees will learn how to adapt their current method of validating FDA-regulated computer systems to align with both GAMP5, Second Edition, published in July 2022, and CSA, a new approach that is subject of a Draft guidance from FDA that was issued in September 2022. These two guidances will reshape the way companies handle validation of computer systems that are based on newer and more innovative technologies.

Rather than avoiding these modern breakthroughs in technology and continuing to rely on older ways of conducting business, attendees will learn how to adapt their current practices and thinking about validation to leverage these innovative tools and advance their ability to bring their companies to a new level of success. Newer technologies will help them bring more advanced products to the marketplace and this can be achieved by learning how to approach validation to continue meeting FDA compliance. These include cloud-based services, Software-as-a-Service (SaaS) solutions, and software that incorporates Artificial Intelligence (AI), Machine Learning (ML) and Large Language Models (LLMs), such as ChatGPT.

Course Agenda:

Day 1 - Foundations & Transition

  • Identifying GxP systems in your organization
  • Overview of traditional Computer System Validation (CSV) based on FDA requirements
  • Introduction to the System Development Life Cycle (SDLC) approach
  • Understanding the FDA draft guidance on Computer Software Assurance (CSA) and differences from CSV
  • How GAMP5, 2nd Edition aligns with CSA and impacts validation work
  • Assessing system size, complexity, business criticality, and risk to develop a comprehensive validation rationale
  • Conducting a risk assessment to support your validation strategy
  • Ensuring risk-based testing of system requirements
  • Preparing a Requirements Traceability Matrix (RTM) as evidence that all requirements are tested

Day 2 - Compliance, Documentation & Post-Transition Practices

  • Maintaining systems in a validated state across the entire life cycle
  • Ensuring data integrity with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original/True Copy, Accurate, Complete, Consistent, Enduring, Available)
  • Key components of 21 CFR Part 11 compliance for electronic records and signatures
  • Validating COTS, cloud-based, and SaaS solutions
  • Best practices for GxP documentation and maintaining compliance with FDA requirements
  • Documenting CSV efforts: requirements, design, development, testing, and operational maintenance
  • Training requirements to support validation efforts
  • Incorporating Organizational Change Management (OCM) to enhance adoption of new technologies
  • Policies and procedures to support ongoing system validation
  • Performing vendor audits to ensure proper oversight
  • Preparing for FDA inspections or audits of GxP computer systems
  • Understanding regulatory influences, current FDA thinking, and trends in compliance and enforcement
  • Implementing industry best practices to optimize validation, maintain compliance, and ensure data integrity throughout the data lifecycle

Interactive Session:

  • Q&A with expert instructors to address real-world challenges

Who Should Attend:

This course is ideal for professionals involved in GxP systems implementation, compliance, and validation, including:

  • Information Technology Analysts, Developers, and Testers
  • Software Quality Assurance Professionals
  • QC/QA Managers and Analysts
  • Analytical Chemists
  • Compliance and Audit Managers
  • Laboratory Managers
  • Automation Analysts
  • Manufacturing and Supply Chain Specialists/Managers
  • Regulatory Affairs and Regulatory Submissions Specialists
  • Risk Management Professionals
  • Clinical Data Analysts, Managers, and Trial Sponsors
  • Computer System Validation Specialists
  • GMP Training Specialists
  • Business Stakeholders / Subject Matter Experts
  • Business System / Application Testers
  • Vendors and Consultants involved in software development, testing, maintenance, and validation within the life sciences industry

For more information about this training visit https://www.researchandmarkets.com/r/c5br1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.43
+4.02 (1.64%)
AAPL  269.38
+0.91 (0.34%)
AMD  245.54
+12.00 (5.14%)
BAC  53.67
+0.47 (0.88%)
GOOG  291.33
+11.63 (4.16%)
META  633.14
+11.43 (1.84%)
MSFT  506.64
+9.82 (1.98%)
NVDA  197.98
+9.83 (5.22%)
ORCL  239.31
+0.05 (0.02%)
TSLA  446.17
+16.65 (3.88%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.